These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
419 related articles for article (PubMed ID: 9815853)
1. Heregulin and agonistic anti-p185(c-erbB2) antibodies inhibit proliferation but increase invasiveness of breast cancer cells that overexpress p185(c-erbB2): increased invasiveness may contribute to poor prognosis. Xu FJ; Stack S; Boyer C; O'Briant K; Whitaker R; Mills GB; Yu YH; Bast RC Clin Cancer Res; 1997 Sep; 3(9):1629-34. PubMed ID: 9815853 [TBL] [Abstract][Full Text] [Related]
2. Overexpression of the c-erbB-2 gene enhanced intrinsic metastasis potential in human breast cancer cells without increasing their transformation abilities. Tan M; Yao J; Yu D Cancer Res; 1997 Mar; 57(6):1199-205. PubMed ID: 9067293 [TBL] [Abstract][Full Text] [Related]
3. Heregulin beta1-activated phosphatidylinositol 3-kinase enhances aggregation of MCF-7 breast cancer cells independent of extracellular signal-regulated kinase. Tan M; Grijalva R; Yu D Cancer Res; 1999 Apr; 59(7):1620-5. PubMed ID: 10197638 [TBL] [Abstract][Full Text] [Related]
4. Growth regulation of human breast and ovarian tumor cells by heregulin: Evidence for the requirement of ErbB2 as a critical component in mediating heregulin responsiveness. Lewis GD; Lofgren JA; McMurtrey AE; Nuijens A; Fendly BM; Bauer KD; Sliwkowski MX Cancer Res; 1996 Mar; 56(6):1457-65. PubMed ID: 8640840 [TBL] [Abstract][Full Text] [Related]
5. Involvement of tyrosine phosphorylation of p185(c-erbB2/neu) in tumorigenicity induced by X-rays and the neu oncogene in human breast epithelial cells. Kang KS; Sun W; Nomata K; Morita I; Cruz A; Liu CJ; Trosko JE; Chang CC Mol Carcinog; 1998 Apr; 21(4):225-33. PubMed ID: 9585252 [TBL] [Abstract][Full Text] [Related]
6. The outcome of heregulin-induced activation of ovarian cancer cells depends on the relative levels of HER-2 and HER-3 expression. Xu F; Yu Y; Le XF; Boyer C; Mills GB; Bast RC Clin Cancer Res; 1999 Nov; 5(11):3653-60. PubMed ID: 10589783 [TBL] [Abstract][Full Text] [Related]
7. Insulin-like growth factor and epidermal growth factor independence in human mammary carcinoma cells with c-erbB-2 gene amplification and progressively elevated levels of tyrosine-phosphorylated p185erbB-2. Ram TG; Dilts CA; Dziubinski ML; Pierce LJ; Ethier SP Mol Carcinog; 1996 Mar; 15(3):227-38. PubMed ID: 8597535 [TBL] [Abstract][Full Text] [Related]
8. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides. Motoyama AB; Hynes NE; Lane HA Cancer Res; 2002 Jun; 62(11):3151-8. PubMed ID: 12036928 [TBL] [Abstract][Full Text] [Related]
9. Ligand-like effects induced by anti-c-erbB-2 antibodies do not correlate with and are not required for growth inhibition of human carcinoma cells. Shawver LK; Mann E; Elliger SS; Dugger TC; Arteaga CL Cancer Res; 1994 Mar; 54(5):1367-73. PubMed ID: 7907001 [TBL] [Abstract][Full Text] [Related]
10. Role of CD44s and CD44v6 on human breast cancer cell adhesion, migration, and invasion. Afify A; Purnell P; Nguyen L Exp Mol Pathol; 2009 Apr; 86(2):95-100. PubMed ID: 19167378 [TBL] [Abstract][Full Text] [Related]
11. Induction of sensitivity to doxorubicin and etoposide by transfection of MCF-7 breast cancer cells with heregulin beta-2. Harris LN; Yang L; Tang C; Yang D; Lupu R Clin Cancer Res; 1998 Apr; 4(4):1005-12. PubMed ID: 9563896 [TBL] [Abstract][Full Text] [Related]
12. Neu differentiation factor (heregulin) induces expression of intercellular adhesion molecule 1: implications for mammary tumors. Bacus SS; Gudkov AV; Zelnick CR; Chin D; Stern R; Stancovski I; Peles E; Ben-Baruch N; Farbstein H; Lupu R Cancer Res; 1993 Nov; 53(21):5251-61. PubMed ID: 8106145 [TBL] [Abstract][Full Text] [Related]
13. Differential signaling by an anti-p185(HER2) antibody and heregulin. Le XF; Vadlamudi R; McWatters A; Bae DS; Mills GB; Kumar R; Bast RC Cancer Res; 2000 Jul; 60(13):3522-31. PubMed ID: 10910064 [TBL] [Abstract][Full Text] [Related]
14. p185c-erbB-2 signal enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair. Arteaga CL; Winnier AR; Poirier MC; Lopez-Larraza DM; Shawver LK; Hurd SD; Stewart SJ Cancer Res; 1994 Jul; 54(14):3758-65. PubMed ID: 7913407 [TBL] [Abstract][Full Text] [Related]
15. Overexpression of ErbB2 enhances ethanol-stimulated intracellular signaling and invasion of human mammary epithelial and breast cancer cells in vitro. Ma C; Lin H; Leonard SS; Shi X; Ye J; Luo J Oncogene; 2003 Aug; 22(34):5281-90. PubMed ID: 12917629 [TBL] [Abstract][Full Text] [Related]
16. In vitro assessment of adhesion molecules expression by human endothelial cells cocultured with c-erbB2-positive and c-erbB2-negative breast carcinoma cell lines. Markowska A; Urasińska E; Domagała W Pol J Pathol; 2008; 59(1):49-54. PubMed ID: 18655371 [TBL] [Abstract][Full Text] [Related]
17. Neu differentiation factor induces ErbB2 down-regulation and apoptosis of ErbB2-overexpressing breast tumor cells. Daly JM; Jannot CB; Beerli RR; Graus-Porta D; Maurer FG; Hynes NE Cancer Res; 1997 Sep; 57(17):3804-11. PubMed ID: 9288791 [TBL] [Abstract][Full Text] [Related]
18. Cell surface density of p185(c-erbB-2) determines susceptibility to anti-p185(c-erbB-2)-ricin A chain (RTA) immunotoxin therapy alone and in combination with anti-p170(EGFR)-RTA in ovarian cancer cells. Dean GS; Pusztai L; Xu FJ; O'Briant K; DeSombre K; Conaway M; Boyer CM; Mendelsohn J; Bast RC Clin Cancer Res; 1998 Oct; 4(10):2545-50. PubMed ID: 9796989 [TBL] [Abstract][Full Text] [Related]
19. Suppression of diacylglycerol levels by antibodies reactive with the c-erbB-2 (HER-2/neu) gene product p185c-erbB-2 in breast and ovarian cancer cell lines. Boente MP; Berchuck A; Whitaker RS; Kalén A; Xu FJ; Clarke-Pearson DL; Bell RM; Bast RC Gynecol Oncol; 1998 Jul; 70(1):49-55. PubMed ID: 9698473 [TBL] [Abstract][Full Text] [Related]
20. Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis. Yen L; You XL; Al Moustafa AE; Batist G; Hynes NE; Mader S; Meloche S; Alaoui-Jamali MA Oncogene; 2000 Jul; 19(31):3460-9. PubMed ID: 10918604 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]